Modified dose of guselkumab for treatment of pyoderma gangrenosum
Ashley M. Reese, Katherine M. Erickson, Katherine B. Reed, Alex G. Ortega‐Loayza
Abstract
Pyoderma gangrenosum (PG) is an ulcerative neutrophilic dermatosis that classically affects the lower extremities. The pathophysiology of PG is incompletely understood, which makes targeted therapeutic approaches challenging. Interleukin (IL) 23, a cytokine implicated in neutrophilic diseases, has shown promise as a PG treatment target.1 We report a case of recalcitrant PG treated with guselkumab (an IL-23 inhibitor) at a dose modified from that approved for other inflammatory conditions.
Topics & Concepts
Pyoderma gangrenosumMedicineDermatologyPathophysiologyInterleukin 23Neutrophilic dermatosisCytokineInterleukinImmunologyInternal medicineDiseaseAutoimmune and Inflammatory DisordersHidradenitis Suppurativa and TreatmentsSkin Diseases and Diabetes